Dataset Information
SILAC proteomics analysis to discover effect sensors of EGFR inhibition
Ontology highlight
ABSTRACT:
INSTRUMENT(S): LTQ Orbitrap
ORGANISM(S): Homo Sapiens (human)
TISSUE(S): Epithelial Cell, Cell Culture
DISEASE(S): Breast Cancer
SUBMITTER: 
Rolf de Boer
LAB HEAD: Marcel A.T.M. van Vugt
PROVIDER: PXD005985 | Pride | 2018-10-18
REPOSITORIES: Pride
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| BT474_batch1_lane1_A01.raw | Raw | |||
| BT474_batch1_lane1_A02.raw | Raw | |||
| BT474_batch1_lane1_A03.raw | Raw | |||
| BT474_batch1_lane1_A04.raw | Raw | |||
| BT474_batch1_lane1_A05.raw | Raw |
Items per page: 1 - 5 of 194 |
Publications
Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.
Oncogene 20181010 9
Tumor responses to cancer therapeutics are generally monitored every 2-3 months based on changes in tumor size. Dynamic biomarkers that reflect effective engagement of targeted therapeutics to the targeted pathway, so-called "effect sensors", would fulfill a need for non-invasive, drug-specific indicators of early treatment effect. Using a proteomics approach to identify effect sensors, we demonstrated MUC1 upregulation in response to epidermal growth factor receptor (EGFR)-targeting treatments ...[more]